{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:56:21Z","timestamp":1762253781280},"reference-count":41,"publisher":"Pharmaceutical Society of Japan","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,5,1]]},"DOI":"10.1248\/bpb.b20-00791","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T22:09:10Z","timestamp":1619820550000},"page":"611-619","source":"Crossref","is-referenced-by-count":4,"title":["Comprehensive Exploration of Medications That Affect the Bleeding Risk of Oral Anticoagulant Users"],"prefix":"10.1248","volume":"44","author":[{"given":"Yohei","family":"Kawano","sequence":"first","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tokyo University of Science (TUS)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Medical Hospital, Tokyo Medical and Dental University (TMDU)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeko","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tokyo University of Science (TUS)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuuki","family":"Akagi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tokyo University of Science (TUS)"},{"name":"Department of Pharmacy, National Hospital Organization Yokohama Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsunori","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tokyo University of Science (TUS)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Tsukada","sequence":"additional","affiliation":[{"name":"Center Hospital of the National Center for Global Health and Medicine (NCGM)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Hoshiko","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tokyo University of Science (TUS)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azusa","family":"Kujirai","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tokyo University of Science (TUS)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Nakamatsu","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tokyo University of Science (TUS)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tokyo University of Science (TUS)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Enomoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Medical Hospital, Tokyo Medical and Dental University (TMDU)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Negishi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tokyo University of Science (TUS)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Shimada","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tokyo University of Science (TUS)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Aoyama","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tokyo University of Science (TUS)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunari","family":"Mano","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tokyo University of Science (TUS)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Kuruvilla M, Gurk-Turner C. A review of warfarin dosing and monitoring. <i>Proc. Bayl. Univ. Med. Cent.<\/i>, <b>14<\/b>, 305\u2013306 (2001).","DOI":"10.1080\/08998280.2001.11927781"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Santarpia G, Curcio A, Sibilio G, Indolfi C. Clinical significance of non-vitamin K antagonist oral anticoagulants in the management of atrial fibrillation. <i>Circ. J.<\/i>, <b>79<\/b>, 914\u2013923 (2015).","DOI":"10.1253\/circj.CJ-15-0319"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace<\/i>, <b>15<\/b>, 625\u2013651 (2013).","DOI":"10.1093\/europace\/eut083"},{"key":"4","unstructured":"4) Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. <i>Lancet<\/i>, <b>383<\/b>, 955\u2013962 (2014)."},{"key":"5","unstructured":"5) Held C, Hylek EM, Alexander JH, Hanna M, Lopes RD, Wojdyla DM, Thomas L, Al-Khalidi H, Alings M, Xavier D, Ansell J, Goto S, Ruzyllo W, Rosenqvist M, Verheugt FW, Zhu J, Granger CB, Wallentin L. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. <i>Eur. Heart J.<\/i>, <b>36<\/b>, 1264\u20131272 (2015)."},{"key":"6","unstructured":"6) Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane DA, Levi M, Marin F, Palareti G, Kirchhof P, Collet JP, Rubboli A, Poli D, Camm J. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace<\/i>, <b>13<\/b>, 723\u2013746 (2011)."},{"key":"7","unstructured":"7) Xu T, Yu X, Ou S, Liu X, Yuan J, Tan X, Chen Y. Adherence to antihypertensive medications and stroke risk: a dose\u2013response meta-analysis. <i>J. Am. Heart Assoc.<\/i>, <b>6<\/b>, e006371 (2017)."},{"key":"8","unstructured":"8) Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, Andersen M, Lassen AT. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. <i>BMJ<\/i>, <b>333<\/b>, 726 (2006)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. <i>Arch. Intern. Med.<\/i>, <b>165<\/b>, 189\u2013192 (2005).","DOI":"10.1001\/archinte.165.2.189"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>Circulation<\/i>, <b>127<\/b>, 634\u2013640 (2013).","DOI":"10.1161\/CIRCULATIONAHA.112.115386"},{"key":"11","unstructured":"11) Kreutz R, Haas S, Holberg G, Lassen MR, Mantovani LG, Schmidt A, Turpie AG. Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions. <i>Br. J. Clin. Pharmacol.<\/i>, <b>81<\/b>, 724\u2013734 (2016)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Pemberton MN, Oliver RJ, Theaker ED. Miconazole oral gel and drug interactions. <i>Br. Dent. J.<\/i>, <b>196<\/b>, 529\u2013531 (2004).","DOI":"10.1038\/sj.bdj.4811224"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Chang SH, Chou IJ, Yeh YH, Chiou MJ, Wen MS, Kuo CT, See LC, Kuo CF. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. <i>JAMA<\/i>, <b>318<\/b>, 1250\u20131259 (2017).","DOI":"10.1001\/jama.2017.13883"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Quinn GR, Singer DE, Chang Y, Go AS, Borowsky LH, Udaltsova N, Fang MC. Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. <i>Am. J. Cardiol.<\/i>, <b>114<\/b>, 583\u2013586 (2014).","DOI":"10.1016\/j.amjcard.2014.05.037"},{"key":"15","unstructured":"15) \u201cFeatures of JMDC Claims Database.\u201d: \u2039https:\/\/www.jmdc.co.jp\/pharma\/database.html\u203a, accessed 11 September, 2020."},{"key":"16","unstructured":"16) Lamberts M, Staerk L, Olesen JB, Fosb\u00f8l EL, Hansen ML, Harboe L, Lefevre C, Evans D, Gislason GH. Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patients. <i>J. Am. Heart Assoc.<\/i>, <b>6<\/b>, e004517 (2017)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, Hamilton M. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. <i>Thromb. Haemost.<\/i>, <b>116<\/b>, 975\u2013986 (2016).","DOI":"10.1160\/TH16-05-0403"},{"key":"18","unstructured":"18) \u201cGastroenterological endoscopy practice guidelines for antithrombotic drug users. (2012 edition)\u201d: \u2039https:\/\/www.jstage.jst.go.jp\/article\/gee\/54\/7\/54_2075\/_pdf.\u203a, accessed 11 September, 2020."},{"key":"19","unstructured":"19) Takahashi A, Mizutani M, Kawai N, Kawano S, Sato N. Double balloon enteroscopy for diagnosis and treatment of small intestinal hemorrhage. <i>J. Abdom. Emerg. Med.<\/i>, <b>27<\/b>, 949\u2013956 (2007)."},{"key":"20","unstructured":"20) Cappell MS, Friedel D. Acute nonvariceal upper gastrointestinal bleeding: endoscopic diagnosis and therapy. <i>Med. Clin. North Am.<\/i>, <b>92<\/b>, 511\u2013550, vii\u2013viii (2008)."},{"key":"21","unstructured":"21) \u201dVarious information of medical fee (2018 edition).\u201d: \u2039http:\/\/shinryohoshu.mhlw.go.jp\/\u203a, accessed 11 September, 2020."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Pincus D, Gomes T, Hellings C, Zheng H, Paterson JM, Mamdani MM, Juurlink DN. A population-based assessment of the drug interaction between levothyroxine and warfarin. <i>Clin. Pharmacol. Ther.<\/i>, <b>92<\/b>, 766\u2013770 (2012).","DOI":"10.1038\/clpt.2012.171"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. <i>Med. Care<\/i>, <b>43<\/b>, 1130\u20131139 (2005).","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. <i>Am. J. Epidemiol.<\/i>, <b>173<\/b>, 676\u2013682 (2011).","DOI":"10.1093\/aje\/kwq433"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. <i>Chest<\/i>, <b>150<\/b>, 1302\u20131312 (2016).","DOI":"10.1016\/j.chest.2016.07.013"},{"key":"26","unstructured":"26) Camm AJ, Kirchhof P, Lip GY, <i>et al.<\/i> Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). <i>Eur. Heart J.<\/i>, <b>31<\/b>, 2369\u20132429 (2010)."},{"key":"27","unstructured":"27) Rothendler JA, Rose AJ, Reisman JI, Berlowitz DR, Kazis LE. Choices in the use of ICD-9 codes to identify stroke risk factors can affect the apparent population\u2013level risk factor prevalence and distribution of CHADS2 scores. <i>Am. J. Cardiovasc. Dis.<\/i>, <b>2<\/b>, 184\u2013191 (2012)."},{"key":"28","unstructured":"28) Schjerning Olsen AM, Lindhardsen J, Gislason GH, McGettigan P, Hlatky MA, Fosb\u00f8l E, K\u00f8ber L, Torp-Pedersen C, Lamberts M. Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study. <i>BMJ<\/i>, <b>351<\/b>, h5096 (2015)."},{"key":"29","unstructured":"29) Chan EW, Lau WC, Leung WK, Mok MT, He Y, Tong TS, Wong IC. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. <i>Gastroenterology<\/i>, <b>149<\/b>, 586\u2013595.e3 (2015)."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, Stein CM. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. <i>Gastroenterology<\/i>, <b>151<\/b>, 1105\u20131112.e10 (2016).","DOI":"10.1053\/j.gastro.2016.08.054"},{"key":"31","unstructured":"31) Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. <i>Eur. Heart J.<\/i>, <b>33<\/b>, 1500\u20131510 (2012)."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Junqueira RM, Duarte EC. Hospitalizations due to ambulatory care-sensitive conditions in the Federal District, Brazil, 2008. <i>Rev. Saude Publica<\/i>, <b>46<\/b>, 761\u2013768 (2012).","DOI":"10.1590\/S0034-89102012000500001"},{"key":"33","unstructured":"33) Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. <i>Am. J. Med.<\/i>, <b>87<\/b>, 144\u2013152 (1989)."},{"key":"34","unstructured":"34) Ishii M, Ogawa H, Unoki T, An Y, Iguchi M, Masunaga N, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Abe M, Akao M. Relationship of hypertension and systolic blood pressure with the risk of stroke or bleeding in patients with atrial fibrillation: the fushimi AF registry. <i>Am. J. Hypertens.<\/i>, <b>30<\/b>, 1073\u20131082 (2017)."},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Conti A, Molesti D, Bianchi S, Catarzi S, Mazzucchelli M, Covelli A, Tognarelli A, Perrotta ME, Pampana A, Orlandi G, Dell\u2019Amico I, Baratta A, Arena G, Torri T. Role of hypertension and other clinical variables in prognostication of patients presenting to the emergency department with major bleeding events. <i>Crit. Pathw. Cardiol.<\/i>, <b>17<\/b>, 139\u2013146 (2018).","DOI":"10.1097\/HPC.0000000000000139"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Kamiyama E, Nakai D, Mikkaichi T, Okudaira N, Okazaki O. Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes. <i>Life Sci.<\/i>, <b>86<\/b>, 52\u201358 (2010).","DOI":"10.1016\/j.lfs.2009.11.006"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Van Aken H, Puchstein C, Fitch W, Graham DI. Haemodynamic and cerebral effects of ATP-induced hypotension. <i>Br. J. Anaesth.<\/i>, <b>56<\/b>, 1409\u20131416 (1984).","DOI":"10.1093\/bja\/56.12.1409"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Hansen ML, S\u00f8rensen R, Clausen MT, Fog-Petersen ML, Rauns\u00f8 J, Gadsb\u00f8ll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstr\u00f8m SZ, Poulsen HE, K\u00f8ber L, Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. <i>Arch. Intern. Med.<\/i>, <b>170<\/b>, 1433\u20131441 (2010).","DOI":"10.1001\/archinternmed.2010.271"},{"key":"39","unstructured":"39) Nishio H, Inoue A, Nakata Y. Binding affinity of sarpogrelate, a new antiplatelet agent, and its metabolite for serotonin receptor subtypes. <i>Arch. Int. Pharmacodyn. Ther.<\/i>, <b>331<\/b>, 189\u2013202 (1996)."},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, Stein CM. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. <i>JAMA<\/i>, <b>320<\/b>, 2221\u20132230 (2018).","DOI":"10.1001\/jama.2018.17242"},{"key":"41","unstructured":"41) Lapner S, Cohen N, Kearon C. Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and meta-analysis. <i>J. Thromb. Haemost.<\/i>, <b>12<\/b>, 595\u2013605 (2014)."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/5\/44_b20-00791\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T03:32:03Z","timestamp":1619839923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/5\/44_b20-00791\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b20-00791","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]}}}